Cargando…
In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival
BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS/HIPEC. The aim of this study was to determi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246798/ https://www.ncbi.nlm.nih.gov/pubmed/35430666 http://dx.doi.org/10.1245/s10434-022-11718-7 |
_version_ | 1784739033716359168 |
---|---|
author | Said, Ibrahim Ubink, Inge Ewalds, Roos S. G. Arkesteijn, Johanna G. T. Verheul, Henk M. W. de Wilt, Johannes H. W. Dekker, Helena M. Bremers, Andreas J. A. de Reuver, Philip R. |
author_facet | Said, Ibrahim Ubink, Inge Ewalds, Roos S. G. Arkesteijn, Johanna G. T. Verheul, Henk M. W. de Wilt, Johannes H. W. Dekker, Helena M. Bremers, Andreas J. A. de Reuver, Philip R. |
author_sort | Said, Ibrahim |
collection | PubMed |
description | BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS/HIPEC. The aim of this study was to determine the prognostic value of ascites diagnosed on preoperative imaging. METHODS: A prospective database of patients eligible for CRS/HIPEC between 2010 and 2020 was retrospectively analyzed. The presence of ascites, postoperative complications, overall survival (OS), disease-free survival (DFS), and completeness of cytoreduction were assessed. Univariable and multivariable logistic regression was performed to identify independent predictors for outcome. RESULTS: Of the 235 included patients, 177 (75%) underwent CRS/HIPEC while 58 (25%) were not eligible for CRS/HIPEC. In 42 of the 177 patients (24%) who underwent CRS/HIPEC, ascites was present on preoperative computed tomography (CT) imaging. Peritoneal Cancer Index (PCI) score was significantly higher in patients with preoperative ascites compared with patients without (11 [range 2–30] vs. 9 [range 0–28], respectively; p = 0.011) and complete cytoreduction was more often achieved in patients without ascites (96.3% vs. 85.7%; p = 0.007). There was no significant difference in median DFS and OS after CRS/HIPEC between patients with and without ascites {10 months (95% confidence interval [CI] 7.1–12.9) vs. 9 months (95% CI 7.2–10.8), and 25 months (95% 9.4–40.6) vs. 27 months (95% CI 22.4–31.6), respectively}. CONCLUSIONS: Ascites on preoperative imaging was not associated with worse survival in CRS/HIPEC patients with CRPM. Therefore, excluding patients from CRS/HIPEC based merely on the presence of ascites is not advisable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11718-7. |
format | Online Article Text |
id | pubmed-9246798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-92467982022-07-02 In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival Said, Ibrahim Ubink, Inge Ewalds, Roos S. G. Arkesteijn, Johanna G. T. Verheul, Henk M. W. de Wilt, Johannes H. W. Dekker, Helena M. Bremers, Andreas J. A. de Reuver, Philip R. Ann Surg Oncol Peritoneal Surface Malignancy BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for patients with colorectal peritoneal metastases (CRPM). Patient selection is key to optimizing outcomes after CRS/HIPEC. The aim of this study was to determine the prognostic value of ascites diagnosed on preoperative imaging. METHODS: A prospective database of patients eligible for CRS/HIPEC between 2010 and 2020 was retrospectively analyzed. The presence of ascites, postoperative complications, overall survival (OS), disease-free survival (DFS), and completeness of cytoreduction were assessed. Univariable and multivariable logistic regression was performed to identify independent predictors for outcome. RESULTS: Of the 235 included patients, 177 (75%) underwent CRS/HIPEC while 58 (25%) were not eligible for CRS/HIPEC. In 42 of the 177 patients (24%) who underwent CRS/HIPEC, ascites was present on preoperative computed tomography (CT) imaging. Peritoneal Cancer Index (PCI) score was significantly higher in patients with preoperative ascites compared with patients without (11 [range 2–30] vs. 9 [range 0–28], respectively; p = 0.011) and complete cytoreduction was more often achieved in patients without ascites (96.3% vs. 85.7%; p = 0.007). There was no significant difference in median DFS and OS after CRS/HIPEC between patients with and without ascites {10 months (95% confidence interval [CI] 7.1–12.9) vs. 9 months (95% CI 7.2–10.8), and 25 months (95% 9.4–40.6) vs. 27 months (95% CI 22.4–31.6), respectively}. CONCLUSIONS: Ascites on preoperative imaging was not associated with worse survival in CRS/HIPEC patients with CRPM. Therefore, excluding patients from CRS/HIPEC based merely on the presence of ascites is not advisable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-11718-7. Springer International Publishing 2022-04-16 2022 /pmc/articles/PMC9246798/ /pubmed/35430666 http://dx.doi.org/10.1245/s10434-022-11718-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Peritoneal Surface Malignancy Said, Ibrahim Ubink, Inge Ewalds, Roos S. G. Arkesteijn, Johanna G. T. Verheul, Henk M. W. de Wilt, Johannes H. W. Dekker, Helena M. Bremers, Andreas J. A. de Reuver, Philip R. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival |
title | In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival |
title_full | In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival |
title_fullStr | In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival |
title_full_unstemmed | In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival |
title_short | In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival |
title_sort | in patients undergoing crs/hipec for colorectal adenocarcinoma with peritoneal metastases, presence of ascites on computed tomography imaging is not a prognostic marker for survival |
topic | Peritoneal Surface Malignancy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246798/ https://www.ncbi.nlm.nih.gov/pubmed/35430666 http://dx.doi.org/10.1245/s10434-022-11718-7 |
work_keys_str_mv | AT saidibrahim inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT ubinkinge inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT ewaldsroossg inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT arkesteijnjohannagt inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT verheulhenkmw inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT dewiltjohanneshw inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT dekkerhelenam inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT bremersandreasja inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival AT dereuverphilipr inpatientsundergoingcrshipecforcolorectaladenocarcinomawithperitonealmetastasespresenceofascitesoncomputedtomographyimagingisnotaprognosticmarkerforsurvival |